First United Arab Emirates Consensus on Diagnosis and Management of Inflammatory Bowel Diseases: A 2020 Delphi Consensus

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2020 Dec 3

PMID 33268959

Citations 9

Authors

Maryam Alkhatry

Ahmad Al-Rifai

Vito Annese

Filippos Georgopoulos

Ahmad N Jazzar

Ahmed M Khassouan

Zaher Koutoubi

Rahul Nathwani

Mazen S Taha

Jimmy K Limdi

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis and Crohn's disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract. The incidence and prevalence are on the rise worldwide, and the heterogeneity between patients and within individuals over time is striking. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients. This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations. Comprehensive up-to-date guidance is provided regarding diagnosis, evaluation of disease severity, appropriate and timely use of different investigations, choice of appropriate therapy for induction and remission phase according to disease severity, and management of main complications.

Citing Articles

Screening and evaluation of key technologies for non-bioartificial liver care: an empirical study.

Zhang Y, Zhang H, Luo L, Liu Z, Liu A, Shi L Front Med (Lausanne). 2025; 11():1459428.

PMID: 39839620 PMC: 11745882. DOI: 10.3389/fmed.2024.1459428.

Regulatory Framework for Supporting the Integration and Use of Biosimilars in the Private Healthcare System of the United Arab Emirates (UAE).

Farghaly M, El-Fass K, Amin N, Qaiser S, Attallah M, Farooq Q Cureus. 2024; 16(11):e74581.

PMID: 39734949 PMC: 11673801. DOI: 10.7759/cureus.74581.

Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Salman A, Salman M, Elewa A, Awwad A Cureus. 2024; 16(6):e61547.

PMID: 38835557 PMC: 11148671. DOI: 10.7759/cureus.61547.

Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.

Nigam G, Chatten K, Sharara A, Al-Taweel T, Alharbi O, Elamin H Therap Adv Gastroenterol. 2024; 17:17562848241230902.

PMID: 38406794 PMC: 10894550. DOI: 10.1177/17562848241230902.

Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases.

Elzayat H, Mesto G, Al-Marzooq F Nutrients. 2023; 15(15).

PMID: 37571313 PMC: 10421146. DOI: 10.3390/nu15153377.

References

Niv Y, Ilani S, Levi Z, Hershkowitz M, Niv E, Fireman Z . Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy. 2011; 44(1):21-6. DOI: 10.1055/s-0031-1291385. View

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. DOI: 10.1053/j.gastro.2003.11.010. View

Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D . Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010; 8(7):591-9.e1. DOI: 10.1016/j.cgh.2010.01.016. View

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

Liu W, Liu J, Xiao W, Luo G . A Diagnostic Accuracy Meta-analysis of CT and MRI for the Evaluation of Small Bowel Crohn Disease. Acad Radiol. 2017; 24(10):1216-1225. DOI: 10.1016/j.acra.2017.04.013. View

Doherty G, Bennett G, Patil S, Cheifetz A, Moss A . Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009; (4):CD006873. DOI: 10.1002/14651858.CD006873.pub2. View

Burisch J, Kiudelis G, Kupcinskas L, Kievit H, Andersen K, Andersen V . Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018; 68(3):423-433. DOI: 10.1136/gutjnl-2017-315568. View

Rokkas T, Portincasa P, Koutroubakis I . Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018; 27(3):299-306. DOI: 10.15403/jgld.2014.1121.273.pti. View

Danese S, Siegel C, Peyrin-Biroulet L . Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014; 39(10):1095-103. DOI: 10.1111/apt.12712. View

10.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J . Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018; 113(9):1345. PMC: 6445254. DOI: 10.1038/s41395-018-0162-0. View

11.

Arasaradnam R, Brown S, Forbes A, Fox M, Hungin P, Kelman L . Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018; 67(8):1380-1399. PMC: 6204957. DOI: 10.1136/gutjnl-2017-315909. View

12.

To N, Ford A, Gracie D . Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016; 44(2):117-26. DOI: 10.1111/apt.13663. View

13.

Ravindran P, Ansari N, Young C, Solomon M . Definitive surgical closure of enterocutaneous fistula: outcome and factors predictive of increased postoperative morbidity. Colorectal Dis. 2014; 16(3):209-18. DOI: 10.1111/codi.12473. View

14.

Harris K, Horst S, Gadani A, Nohl A, Annis K, Duley C . Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab. Inflamm Bowel Dis. 2016; 22(2):397-401. DOI: 10.1097/MIB.0000000000000624. View

15.

McSharry K, Dalzell A, Leiper K, El-Matary W . Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther. 2011; 34(11-12):1282-94. DOI: 10.1111/j.1365-2036.2011.04873.x. View

16.

Arnold G, Beaves M, Pryjdun V, Mook W . Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002; 8(1):10-5. DOI: 10.1097/00054725-200201000-00002. View

17.

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

18.

Henriksen M, Jahnsen J, Lygren I, Vatn M, Moum B . Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol. 2007; 102(9):1955-63. DOI: 10.1111/j.1572-0241.2007.01368.x. View

19.

Rubin D, Cohen R, Sandborn W, Lichtenstein G, Axler J, Riddell R . Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017; 11(7):785-791. PMC: 5881669. DOI: 10.1093/ecco-jcc/jjx032. View

20.

Ma X, Li Y, Jia H, Zhang J, Wang G, Liu X . Contrast-enhanced ultrasound in the diagnosis of patients suspected of having active Crohn's disease: meta-analysis. Ultrasound Med Biol. 2015; 41(3):659-68. DOI: 10.1016/j.ultrasmedbio.2014.09.013. View